Clinical characteristics, genomic profiling, treatments, and outcomes of Langerhans Cell Sarcoma

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background: Langerhans cell sarcoma (LCS), an exceptionally rare and aggressive neoplasm, remains poorly characterized due to its scarcity. To address this knowledge gap, we conducted a retrospective analysis of 13 LCS patients. This retrospective study included patients ≥18 years old with biopsy proven LCS from October 2015 to April 2025. Results: The median age at diagnosis was 59 years (range: 33-71). The mostcommonly affected organs were the subcutaneous soft tissue (61.5%), followed by lymph nodes (53.8%), skin (30.8%), and bone (23.1%). CBL was the most common mutation, detected in four patients (33.3%). Notably, first-line treatment options included surgery and chemotherapy, with an overall response rate of 53.8%. Among all the relapsed or refractory patients, three eventually received targeted therapies (two trametinib and one niraparib), demonstrating promising efficacy with all patients achieved partial remission. With a median follow-up of 18.2 months (range: 2.6-93.1), the estimated 2-year overall survival rate was 92.3%, while the estimated 2-year progression-free survival rate stood at 32.9%. Conclusions: In our cohort of LCS, we found that prognosis of LCS was poor. Genetic sequencing and the use of targeted therapies may offer a survival advantage for patients with LCS.

Article activity feed